NDMC101

NDMC101 is a potent osteoclastogenesis inhibitor and inhibits osteoclast differentiation via down-regulation of NFATc1-modulated gene expression. NDMC101 is similar to the DPP4 substrate and is a significant inhibitor of early T-cell activation via DPP4 inhibition. NDMC101can be used for study of bone disorders, such as rheumatoid arthritis, and synovial inflammation et al[1].

Product Specifications

CAS Number

[1308631-40-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Dipeptidyl Peptidase; NF-κB

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; NF-κB

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ndmc101.html

Concentration

10mM

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC1=C(C=CC=C1)C(NC2=CC=C(C=C2F)Cl)=O

Molecular Formula

C13H9ClFNO2

Molecular Weight

265.67

Precautions

H302, H315, H319, H335

References & Citations

[1]Chia-Pi Cheng, et al. A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: a potential osteoclastogenesis inhibitor for experimental arthritis. J Clin Immunol. 2012 Aug;32 (4) :762-77.|[2]Jun-Ting Liou, et al. A salicylate-based small molecule HS-Cm exhibits immunomodulatory effects and inhibits dipeptidyl peptidase-IV activity in human T cells. Eur J Pharmacol. 2014 Mar 5;726:124-32.